Abstract:This article highlights the potential of azole derivatives in cancer therapy, focusing on their ability to target cancer cells and disrupt key biological pathways. It discusses recent advances, structural modifications, and ongoing research aimed at enhancing their anticancer efficacy. The review accentuates the therapeutic promise of azoles in developing innovative treatments for cancer. Monocyclic 5‐membered heterocycles including imidazoles, thiazoles, oxazoles, and their related compounds have gained significant attention in medicinal chemistry because of their potent anticancerous activity. These small heterocyclic molecules possess versatile properties, including biological activity, absorption, distribution, metabolism, excretion, and chemical diversity that give them immense potential as anticancer agents. It is also a fact that inherent characteristic of azoles to combine with many biological molecules through hydrogen bond, stacking, and hydrophobic interaction makes them effective against almost all cancer types. In the present paper the author discusses the way which is connected with chemical structure of monocyclic azoles and their anticancer activity namely the ability of these compounds to intercalate with DNA, to inhibit some enzymes and to interfere cellular signaling pathways. Interestingly, several azole derivatives have been seen to be effective in preclinical efficacy studies as well as in clinical trials and are considered to be potent in overcoming the problem of resistance and side effects of the common anticancer agents. As the synthetic chemistry progresses, the structural system of the azoles has diversified and development in the pharmacology has become more specific. This has helped in enhancing the formation of new molecules in the azole class with improved selectivity and efficacy. Furthermore, the comprehensive review explains how computational chemistry and structure‐activity relationship (SAR) approaches are applied to the design of future‐generation azole compounds. In light of these facts, this article is designed to give a broad overview of the current state of monocyclic azole‐based anticancer agents in an attempt to further assert its therapeutic promise and spur further attempts at infusing the said agents into the cancer therapeutics fray. The discoveries made in this study may allow the development the radical different therapeutic approaches, which could lead to improved and targeted treatment of cancer.

Structural modification strategies of triazoles in anticancer drug development

Recent Updates on 1,2,3‐, 1,2,4‐, and 1,3,5‐triazine Hybrids (2017–present): the Anticancer Activity, Structure–activity Relationships, and Mechanisms of Action

Bis-triazole-containing Compounds with Anticancer Potential: A Short Re-view

Exploring the Anticancer Potential of Triazine Derivatives: An Outlook of Designing Strategies, Docking Studies, and Structure‐Activity Relationships (SAR)

1,2,3‐Triazole hybrids as anticancer agents: A review

Rational design of 1,2,3-triazole hybrid structures as novel anticancer agents: synthesis, biological evaluation and molecular docking studies

Application of triazoles in the structural modification of natural products

Recent Advances in the Biological Activity of s-Triazine Core Compounds

Recent Advances in the Development of Pyrazole Derivatives as Anticancer Agents

Antitumor Activity of s-Triazine Derivatives: A Systematic Review

Azole Derivatives: Cutting‐Edge Agents in Cancer Therapy

Structure-based approaches for the design of 6-aryl-1-(3,4,5-trimethoxyphenyl)-1H-benzo[d][1,2,3]triazoles as tubulin polymerization inhibitors

Recent progress on triterpenoid derivatives and their anticancer potential

Recent development of azole-sulfonamide hybrids with the anticancer potential

Green Approach Toward Triazole Forming Reactions for Developing Anticancer Drugs

Pyridazine as a privileged structure: An updated review on anticancer activity of pyridazine containing bioactive molecules

Recent contributions of pyridazine as a privileged scaffold of anticancer agents in medicinal chemistry: An updated review

1,2,3-Triazole-Containing Compounds as Anti-Lung Cancer Agents: Current Developments, Mechanisms of Action, and Structure-Activity Relationship

Recent Advances in Structural Optimization of Quinazoline-Based Protein Kinase Inhibitors for Cancer Therapy (2021–Present)

Synthetic Methodology, SAR and Pharmacology of Commercialized Preparations Employing 1, 2, 4‐Triazole Analogues

A comprehensive overview of coumarinyl-triazole hybrids as anticancer agents